Compositions comprising a crac inhibitor and a corticosteroid and methods of use thereof
SG11202005208QA
Composition and method for treating peripheral t-cell lymphoma and cutaneous t-cell lymphoma
BR112020008219A2
calcium channel modulators activated by calcium release to treat hematological and solid cancers
WO2019082124A1
Composition and method for treating diffuse large b-cell lymphoma
AU2018353533A1
CRAC channel modulators for treating esophageal cancer
US2017266196A1
Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals
CA2958988A1
Method of treatment and compositions comprising a dual pi3k delta-gamma kinase inhibitor and a corticosteroid
AP2017009670A0
Substituted chromene derivatives as selective dual inhibitors of PI3 delta and gamma protein kinases
US2017121336A1
Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations
WO2015101958A2
Inhibitors of glutaminase
US2016207929A1
Pi3k protein kinase inhibitors, particularly delta and/or gamma inhibitors
US2014364447A1
Dual selective PI3 delta and gamma kinase inhibitors
CN111904962A
Pharmaceutical composition containing PDE4 inhibitor and PI3 or dual PI 3-gamma kinase inhibitor
US2014011819A1
Selective PI3K delta inhibitors
CN108084138A
Prepare the method and its pharmaceutical applications of optical voidness 2- (1- hydroxyl-alkyls)-chromen-4-one derivatives
WO2013144737A2
Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases
NZ715471A
Novel 2,5- or 2,6-disubstituted bicyclic heteroaryl compounds as modulators of gpr-119
AU2012250576A1
Novel compounds as modulators of protein kinases
CN102958925A
Pyrazoles derivatives modulators of calcium release -activated calcium channel and methods for treatment of non- small cell lung cancer
US2011105447A1
Modulators of calcium release-activated calcium channel
